← Back to Search
Pemetrexed–cisplatin Combination In Mesothelioma
M. Reck, U. Gatzemeier
Published 2005 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Despite the desperate struggle for improvement in the therapy of malignant pleural mesothelioma in previous decades, no standard therapy could be established. Pemetrexed (Alimta®), a new multitargeted antifolate, showed significant antitumor activity in combination with cisplatin compared with cisplatin alone in patients with unresectable pleural mesothelioma. Furthermore, this improved efficacy was transformed into a significant symptomatic benefit. These data led to the approval of the drug by the US Food and Drug Administration and recently by the European Medicines Evaluation Agency for this combination in malignant pleural mesothelioma, and consequently founded the first standard of treatment in this disease. This review reflects the development of chemotherapy in malignant pleural mesothelioma, discusses the results of the EMPHACIS trial, and outlines further developments for pemetrexed-containing regimens in malignant pleural mesothelioma.
This paper references
Combination Chemotherapy With Mitoxantrone, Methotrexate, and Mitomycin (MMM Regimen) in Malignant Pleural Mesothelioma: A Phase II Study
C. Pinto (2001)
•• Phase I trial that demonstrated the activity of the combination of cisplatin plus pemetrexed against mesothelioma
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Clinical benefit algorithm for malignant pleural mesothelioma: results from randomized trial of pemetrexed plus cisplatin versus cisplatin
A Liepa (2002)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Pemetrexed (Alimta®): a novel multitargeted antifolate agent
A. Adjei (2003)
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
The activity of raltitrexed in malignant pleural mesothelioma: an EORTC Phase II study (08992)
P Baas (2003)
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized Phase II studies
N Pavlakis (2002)
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
[Malignant pleural mesothelioma].
Q. Kong (1983)
A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).
P. Janne (2004)
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
C. Linder (1998)
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.
M. Soubra (1990)
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
P. Baas (2003)
Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM).
L. Garland (2004)
• Established the routine use of computed tomography scans for evaluation of response in malignant pleural mesothelioma (MPM)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
• First systematic meta-analysis of chemotherapy results in pleural mesothelioma by analyzing 83 studies
Survival after conservative management of pleural malignant mesothelioma
N Merritt (2001)
Analysis that showed the clinical and symptomatic benefit of chemotherapy with cisplatin and pemetrexed in MPM
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma
M. Halme (1999)
An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
H. Calvert (1999)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument
R J Gralla (2003)
• First reported study dedicated to second-line chemotherapy in MPM
Phase III trial that documented the superiority of pemetrexed and cisplatin versus cisplatin
Asbestos-related diseases of the lung and other organs: their epidemiology and implications for clinical practice.
M. Becklake (1976)
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
S. Tomek (2003)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
HG Bischoff (1998)
Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY-231514) in combination with cisplatin
R Thodtmann (1999)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
P. Jänne (2002)
An explosive course of squamous cell penile cancer in an AIDS patient.
C. Théodore (2002)
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
C. Niyikiza (2002)
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway.
I. Mórocz (1994)
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
N. Vogelzang (1994)
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
• Excellent review of chemotherapy results in MPM
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
O-26 Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies
N. Pavlakis (2003)
Correlation of pulmonary function tests with best tumor response status: results from the Phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma
P Paloetti (2003)
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
Phase III trial in MPM evaluating the antifolate raltitrexed and cisplatin versus cisplatin
Advances in the management of malignant mesothelioma
Mazen Y. Khalil (2003)
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
The EORTC and drug development
D. Lacombe (2002)
Oxaliplatin and Raltitrexed in the Treatment of Inoperable Malignant Pleural Mesothelioma: Results of a Pilot Study
R. Maisano (2001)
Phase II trial of ZD0473 as second-line therapy in mesothelioma.
G. Giaccone (2002)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Phase II study of pemetrexed with and without folic acid and vitamin B 12 as front-line therapy in malignant pleural mesothelioma
G V Scagliotti (2003)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Edatrexate with or without leucovorin rescue for malignant mesothelioma. Sequential Phase II trials by the Cancer and Leukaemia
HL Kindler (1999)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
Edatrexate with or without leucovorin rescue for malignant mesothelioma. Sequential Phase II trials by the Cancer and Leukaemia Group B
H L Kindler (1999)
Asbestosis-related diseases of the lung and other organs: their epidemiology and implications for clinical practice
MR Becklake (1976)
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC.
J. Van Meerbeeck (2004)
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
This paper is referenced by
Uncommon Thoracic Tumors
R. Rengan (2011)
Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth.
F. Guillot (2011)
Chapter 46 – Uncommon Thoracic Tumors
J. Zeng (2016)
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
B. Doonan (2017)
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
Ranjit K Goudar (2008)
Advances in diagnosis and treatment of malignant mesothelioma
J.P.J.J. Hegmans (2006)
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
H. Ando (2015)